← Leaderboards
Laura J Van't Veer
University Of California, San Francisco
$11,693,569
Attributed
$25,367,534
Total exposure
14
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.4M · FY2011–25$10M$7.5M$5M$2.5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$52,115,208 · 18
By mechanism
U54$28,294,187 · 7
P01$12,765,054 · 6
P50$4,202,265 · 1
R01$3,290,798 · 1
U01$2,894,323 · 1
P30$668,581 · 2
Top collaborators
- David H Haussler33 shared
- David Patterson29 shared
- Andrea Hope Bild5 shared
- Lisa M Coussens5 shared
- Heike Elizabeth Daldrup-Link5 shared
- Joe W. Gray5 shared
- William Evan Johnson5 shared
- Matthew F Krummel5 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Diane V Havlir$125,216,731
- Monica Gandhi$27,077,063
- Craig R Cohen$97,239,582
- Moon S Chen$20,241,983
- Tracey J. Woodruff$21,216,565
Others in their field
Top investigators on “Malignant Breast Neoplasm”
- David Heimbrook · Leidos Biomedical Research, Inc.$347,312,063
- Norman Wolmark · Nsabp Foundation, Inc.$122,067,540
- Walter John Curran · Thomas Jefferson University$97,002,422
- Monica M Bertagnolli · Strang Cancer Prevention Center$84,975,759
- Joseph P. Costantino · University Of Pittsburgh At Pittsburgh$68,847,428
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$60,763,376
Research focus
Malignant Breast NeoplasmGenomicsMalignant NeoplasmsBaseTumorPathway InteractionsResponseClinical TrialsProgramsDesignHigh RiskBig DataMolecularBiologyCommunitiesWomanData SetBenchmarkingPhenotypeFundingResearch InfrastructureSan FranciscoComputer SoftwareImproved Outcome
Grant awards (72)
WISDOM: A platform to optimize subtype-specific screening and prevention$3,350,587
P01 · FY2025 · CA
Project 3: Characterization of the biology of non-responders using Imaging and molecular analysis to inform treatment$1,106,270
P01 · FY2025 · CA · contact PI
Project 3: Integration of mammographic AI, clinical, and genomics information to improve breast cancer subtype- specific risk-based screening and prevention$733,345
P01 · FY2025 · CA
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer$670,225
R01 · FY2025 · CA · contact PI
Project 2: Optimizing polygenic risk scores to inform breast cancer screening and prevention$514,780
P01 · FY2025 · CA
Core D: Patient Centered Outcomes and Risk Communication$317,348
P01 · FY2025 · CA
WISDOM: A platform to optimize subtype-specific screening and prevention$3,537,456
P01 · FY2024 · CA
Project 3: Characterization of the biology of non-responders using Imaging and molecular analysis to inform treatment$1,084,062
P01 · FY2024 · CA · contact PI
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer$636,712
R01 · FY2024 · CA · contact PI
Project 3: Characterization of the biology of non-responders using Imaging and molecular analysis to inform treatment$865,755
P01 · FY2023 · CA · contact PI
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer$656,820
R01 · FY2023 · CA · contact PI
Breast Oncology Program$183,250
P30 · FY2023 · CA · contact PI
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer$656,818
R01 · FY2022 · CA · contact PI
Breast Oncology Program$87,279
P30 · FY2022 · CA · contact PI
Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer$670,223
R01 · FY2021 · CA · contact PI
Project 03 - Understanding the biology of non-responders to inform treatment selection$159,389
P01 · FY2021 · CA · contact PI
Breast Oncology Program$122,428
P30 · FY2021 · CA · contact PI
Project 03 - Understanding the biology of non-responders to inform treatment selection$228,726
P01 · FY2020 · CA · contact PI
Breast Oncology Program$79,592
P30 · FY2020 · CA · contact PI
Project 03 - Understanding the biology of non-responders to inform treatment selection$281,011
P01 · FY2019 · CA · contact PI
Breast Oncology Program$86,716
P30 · FY2019 · CA · contact PI
Center for Big Data in Translational Genomics$1,010,185
U54 · FY2018 · HG
Data Scientific Research$569,833
U54 · FY2018 · HG
Administration$388,352
U54 · FY2018 · HG
Project 03 - Understanding the biology of non-responders to inform treatment selection$296,773
P01 · FY2018 · CA · contact PI
Breast Oncology Program$86,469
P30 · FY2018 · CA · contact PI
Training Subproject$46,858
U54 · FY2018 · HG
Breast Oncology Program$10,744
P30 · FY2018 · CA · contact PI
Breast Oncology Program$8,603
P30 · FY2018 · CA · contact PI
BD2K Consortium Activities$5,142
U54 · FY2018 · HG
Breast Oncology Program$3,500
P30 · FY2018 · CA · contact PI
Center for Big Data in Translational Genomics$2,897,217
U54 · FY2017 · HG
Administration$1,698,879
U54 · FY2017 · HG
Data Scientific Research$1,013,769
U54 · FY2017 · HG
Center for Big Data in Translational Genomics$574,845
U54 · FY2017 · HG
Project 03 - Understanding the biology of non-responders to inform treatment selection$289,552
P01 · FY2017 · CA · contact PI
BD2K Consortium Activities$112,886
U54 · FY2017 · HG
Training Subproject$71,683
U54 · FY2017 · HG
Center for Big Data in Translational Genomics$2,753,942
U54 · FY2016 · HG
Data Scientific Research$1,989,056
U54 · FY2016 · HG
Integrative signaling models to decipher complex cancer phenotypes$514,480
U01 · FY2016 · CA
Center for Big Data in Translational Genomics$460,314
U54 · FY2016 · HG
Administration$424,041
U54 · FY2016 · HG
Center for Big Data in Translational Genomics$290,890
U54 · FY2016 · HG
BD2K Consortium Activities$244,426
U54 · FY2016 · HG
Center for Big Data in Translational Genomics$213,354
U54 · FY2016 · HG
Training Subproject$96,419
U54 · FY2016 · HG
Center for Big Data in Translational Genomics$2,753,942
U54 · FY2015 · HG
Data Scientific Research$1,986,537
U54 · FY2015 · HG
Center for Big Data in Translational Genomics$745,942
U54 · FY2015 · HG
Integrative signaling models to decipher complex cancer phenotypes$651,183
U01 · FY2015 · CA
Center for Big Data in Translational Genomics$463,333
U54 · FY2015 · HG
Center for Big Data in Translational Genomics$441,289
U54 · FY2015 · HG
Administration$410,011
U54 · FY2015 · HG
Delineation of Leukocyte Biomarkers for Human Breast Cancer Outcome$354,487
U54 · FY2015 · CA
BD2K Consortium Activities$254,678
U54 · FY2015 · HG
Center for Big Data in Translational Genomics$244,188
U54 · FY2015 · HG
Training Subproject$102,716
U54 · FY2015 · HG
Center for Big Data in Translational Genomics$1,996,651
U54 · FY2014 · HG
Data Scientific Research$1,428,663
U54 · FY2014 · HG
Integrative signaling models to decipher complex cancer phenotypes$551,268
U01 · FY2014 · CA
Delineation of Leukocyte Biomarkers for Human Breast Cancer Outcome$504,942
U54 · FY2014 · CA
Administration$309,039
U54 · FY2014 · HG
BD2K Consortium Activities$189,107
U54 · FY2014 · HG
Training Subproject$69,842
U54 · FY2014 · HG
Integrative signaling models to decipher complex cancer phenotypes$553,275
U01 · FY2013 · CA
Delineation of Leukocyte Biomarkers for Human Breast Cancer Outcome$365,455
U54 · FY2013 · CA
SPORE in Breast Cancer$2,300,000
P50 · FY2012 · CA · contact PI
Integrative signaling models to decipher complex cancer phenotypes$624,117
U01 · FY2012 · CA
Leukocyte Biomarkers for Predicting Human Breast Cancer Outcomes$411,273
U54 · FY2012 · CA
SPORE in Breast Cancer$1,902,265
P50 · FY2011 · CA · contact PI
Leukocyte Biomarkers for Predicting Human Breast Cancer Outcomes$400,001
U54 · FY2011 · CA